Home/ Supplements/ Electrolytes/ DLPA 750 mg

DLPA 750 mg

product on market Tablet or Pill Source Naturals Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • Limited research evidence available for ingredients
B Label Compliance Grade
Label

Product Label

Label for DLPA 750 mg
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
60
Servings
Amino acid/Protein
Product Type
0%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Calcium
55 mg (4% DV)
DL-Phenylalanine
750 mg

Other Ingredients

Dibasic Calcium Phosphate Stearic Acid Sorbitol Magnesium Stearate Silica modified Cellulose Gum
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Suggested Use: 1 tablet 1 to 3 times daily.

Warnings & Precautions

Warning: Contains phenylalanine.

Not to be used by phenylketonurics, women who are pregnant, may become pregnant, or breastfeeding, or with antidepressant drugs containing MAO or SSR inhibitors.

If you have chronic high blood pressure, take after meals and/or consult your health care professional.

Do not use if either tamper-evident seal is broken or missing.

Keep out of the reach of children.

Formulation Notes

DL-Phenylalanine supports an alert state

DL-Phenylalanine, or DLPA, is a 50/50 mixture of the D- and L-forms of the amino acid phenylalanine (phenylalanine is one of the few amino acids that can be utilized in its D form). Researchers believe that D-phenylalanine (DPA) inhibits the action of an enzyme that breaks down endorphins and enkephalins. These are proteins that bind to opioid receptor sites in the brain, thereby influencing the perception of discomfort. By obstructing the action of this enzyme, DPA may extend the life of endorphins and enkephalins and their positive influence on comfort levels. L-Phenylalanine is the precursor to two neurotransmitters that help support an alert state.

Metadata

Product Details

UPC / SKU0 21078 00165 2
DSLD Entry Date2022-09-22
Product TypeAmino acid/Protein
FormTablet or Pill
DSLD ID272416
Data Updated2026-04-11
Research

Research Evidence

849
Research Sources
56
Avg Quality
450
Meta Analysis
152
Rct
137
Systematic Review
73
Clinical Trial
11
Regulatory Source
7
Other
7
Guideline
3
Openfda Safety
2
Cochrane Review
2
Observational
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes
Meta Analysis The Cochrane database of systematic reviews 2015 PubMed DOI
A Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps
Systematic Review The Cochrane database of systematic reviews 2008 PubMed DOI
A Calcium and vitamin D for increasing bone mineral density in premenopausal women
Systematic Review The Cochrane database of systematic reviews 2023 PubMed DOI
A Dietary sodium, sodium-to-potassium ratio, and risk of stroke: A systematic review and nonlinear dose-response meta-analysis
Meta Analysis Clinical nutrition (Edinburgh, Scotland) 2019 PubMed DOI
A The association between circulating magnesium and clinically relevant outcomes in patients with chronic kidney disease: A systematic review and meta-analysis
Meta Analysis Clinical nutrition (Edinburgh, Scotland) 2021 PubMed DOI
A Calcium channel blockers versus other classes of drugs for hypertension
Systematic Review The Cochrane database of systematic reviews 2021 PubMed DOI
View all evidence for Electrolytes →
Compare

Similar Products

View all Electrolytes products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.